Point of View: Tuberculosis innovations mean little if they cannot save lives

  1. Madhukar Pai  Is a corresponding author
  2. Jennifer Furin
  1. McGill University, Canada
  2. Manipal University, India
  3. Harvard Medical School, United States
2 figures

Figures

Cumulative number of GeneXpert instrument modules and Xpert MTB/RIF cartridges procured under concessional pricing since 2010.

As of 31 December 2016, a total of 6,659 GeneXpert instruments (comprising 29,865 modules) and 23,140,350 Xpert MTB/RIF cartridges had been procured in the public sector in 130 of the 145 countries eligible for concessional pricing. Source: Cepheid & WHO (World Health Organization, 2017a).

https://doi.org/10.7554/eLife.25956.002
Progress in bedaquiline (BDQ) and delamanid (DLM) global uptake by month compared with estimated need (goal).

Source: DR-TB STAT (DR-TB STAT, 2017).

https://doi.org/10.7554/eLife.25956.003

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Madhukar Pai
  2. Jennifer Furin
(2017)
Point of View: Tuberculosis innovations mean little if they cannot save lives
eLife 6:e25956.
https://doi.org/10.7554/eLife.25956